Follow The Filings

ALKS Alkermes

Alkermes earnings company data as of 8:01 PM ET 10/22

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ALKS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ALKS insider trades
  • None no insider bought on the open market
  • $2.9M sold by 2 insiders outside a trading plan
  • $7.4M sold by 6 insiders under 10b5-1 plans
  1. David Joseph Gaffin EVP, CLO, Alkermes, Inc.
    Planned sale
    $83K 2,034 shares at $41.03 0.9% of stake
    Traded Oct 2 Filed Oct 2
    ↗
  2. David Joseph Gaffin EVP, CLO, Alkermes, Inc.
    Planned sale
    $98K 2,034 shares at $48.01 0.9% of stake
    Traded Sep 3 Filed Sep 3
    ↗
  3. Craig C. Hopkinson EVP R&D, Chief Medical Officer
    Planned sale
    $423K 9,000 shares at $46.99 12% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  4. Christian Todd Nichols SVP, Chief Commercial Officer
    Planned sale
    $373K 7,576 shares at $49.23 6.9% of stake
    Traded Aug 17 Filed Aug 17
    ↗
  5. Nancy Lynn Snyderman MD Director
    Sale
    $2.2M 44,472 shares at $50.35 74% of stake
    Traded Aug 3 Filed Aug 3
    ↗
  6. Craig C. Hopkinson EVP R&D, Chief Medical Officer
    Planned sale
    $437K 9,000 shares at $48.58 12% of stake
    Traded Aug 3 Filed Aug 3
    ↗
  7. David Joseph Gaffin EVP, CLO, Alkermes, Inc.
    Planned sale
    $99K 2,034 shares at $48.58 0.9% of stake
    Traded Aug 3 Filed Aug 3
    ↗
  8. David Joseph Gaffin EVP, CLO, Alkermes, Inc.
    Planned sale
    $110K 2,034 shares at $54.03 0.9% of stake
    Traded Jul 6 Filed Jul 6
    ↗
  9. Craig C. Hopkinson EVP R&D, Chief Medical Officer
    Planned sale
    $464K 9,000 shares at $51.51 11% of stake
    Traded Jul 1 Filed Jul 1
    ↗
  10. Christopher I Wright Director
    Planned sale
    $90K 2,000 shares at $45.10 7.2% of stake
    Traded Jun 12 Filed Jun 12
    ↗
  11. David Joseph Gaffin EVP, CLO, Alkermes, Inc.
    Planned sale
    $88K 2,034 shares at $43.05 0.9% of stake
    Traded Jun 4 Filed Jun 4
    ↗
  12. Craig C. Hopkinson EVP R&D, Chief Medical Officer
    Planned sale
    $375K 9,000 shares at $41.67 10% of stake
    Traded Jun 1 Filed Jun 1
    ↗
  13. Samuel Joseph Parisi VP, Finance (Interim PAO)
    Sale
    $687K 16,217 shares at $42.36 68% of stake
    Traded May 29 Filed May 29
    ↗
  14. David Joseph Gaffin EVP, CLO, Alkermes, Inc.
    Planned sale
    $68K 2,034 shares at $33.20 0.9% of stake
    Traded May 4 Filed May 4
    ↗
  15. Craig C. Hopkinson EVP R&D, Chief Medical Officer
    Planned sale
    $301K 9,000 shares at $33.40 10% of stake
    Traded May 1 Filed May 1
    ↗

Also filed in the last 12 months, not counted as buying or selling: 47 option exercises, 35 share withholdings for taxes, and 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K/A 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 1.02 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEFA14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.